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1. Introduction
Current paradigms for testing drug effi-
cacy and toxicity are time-consuming, 
ineffective, and expensive.[1] One of the 
main reasons is that the animal models 
used in drug screening are often inef-
fective at predicting human responses 
to candidate drugs.[2] In addition, ethical 
issues surrounding the use of animals for 
these studies have grown exponentially 
in the past few years.[3] Therefore, there 
is an increasing demand for improved in 
vitro 3D organ models that better predict 
the physiological responses of the human 
body to novel pharmaceutical compounds, 
particularly with respect to tissue/organ 
toxicity. While conducting drug discovery 
studies on organ constructs it is crucial to 
keep track of the viability and metabolic 
activity of the tissue constructs/organoids. 
Soluble biomolecules secreted by cells can 
Development of an efficient sensing platform capable of continual monitoring 
of biomarkers is needed to assess the functionality of the in vitro organoids and 
to evaluate their biological responses toward pharmaceutical compounds or 
chemical species over extended periods of time. Here, a novel label-free micro-
fluidic electrochemical (EC) biosensor with a unique built-in on-chip regeneration 
capability for continual measurement of cell-secreted soluble biomarkers from 
an organoid culture in a fully automated manner without attenuating the sensor 
sensitivity is reported. The microfluidic EC biosensors are integrated with a 
human liver-on-a-chip platform for continual monitoring of the metabolic activity 
of the organoids by measuring the levels of secreted biomarkers for up to 7 d, 
where the metabolic activity of the organoids is altered by a systemically applied 
drug. The variations in the biomarker levels are successfully measured by the 
microfluidic regenerative EC biosensors and agree well with cellular viability and 
enzyme-linked immunosorbent assay analyses, validating the accuracy of the 
unique sensing platform. It is believed that this versatile and robust microfluidic 
EC biosensor that is capable of automated and continual detection of soluble 
biomarkers will find widespread use for long-term monitoring of human orga-
noids during drug toxicity studies or efficacy assessments of in vitro platforms.
Dr. S. R. Shin, Dr. T. Kilic, Dr. Y. S. Zhang, Dr. H. Avci, Dr. N. Hu,  
Dr. D. Kim, C. Branco, J. Aleman, Dr. S. Massa, A. Silvestri, J. Kang,  
A. Desalvo, Dr. S.-K. Chae, Dr. A. Polini, Dr. N. Bhise, Dr. Dokmeci,  
Dr. A. Khademhosseini
Biomaterials Innovation Research Center
Department of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA 02139, USA
E-mail: sshin4@partners.org; mdokmeci@rics.bwh.harvard.edu;  
alik@bwh.harvard.edu
Dr. S. R. Shin, Dr. T. Kilic, Dr. Y. S. Zhang, Dr. H. Avci, Dr. N. Hu,  
Dr. D. Kim, C. Branco, J. Aleman, Dr. S. Massa, A. Silvestri, J. Kang,  
A. Desalvo, Dr. S.-K. Chae, Dr. A. Polini, Dr. N. Bhise,  
Dr. M. R. Dokmeci, Dr. A. Khademhosseini
Harvard-MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology
Cambridge, MA 02139, USA
Dr. T. Kilic
Izmir Katip Celebi University
Faculty of Engineering and Architecture
Department of Biomedical Engineering
35620 Izmir, Turkey
Dr. H. Avci
Department of Metallurgical and Materials Engineering
Faculty of Engineering and Architecture
Eskisehir Osmangazi University
26040 Eskisehir, Turkey
Dr. N. Hu
Biosensor National Special Laboratory
Key Laboratory of Biomedical Engineering  
of Ministry of Education
Department of Biomedical Engineering
Zhejiang University
Hangzhou, Zhejiang 310027, P. R. China
C. Branco, A. Silvestri, J. Kang
Politecnico di Torino
Department of Electronics and Telecommunications (DET)
Corso Duca degli Abruzzi 24, 10129 Torino, Italy
www.advancedscience.com
Adv. Sci. 2017, 4, 1600522
www.advancedsciencenews.com
Fu
ll
 p
a
p
er
1600522 (2 of 14) wileyonlinelibrary.com © 2017 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
be used as indicators to assess the functionality of the in vitro 
organoids and evaluate their biological responses toward phar-
maceutical compounds or toxic chemical species.[4] Quantitative 
detection of biomarkers in complex biological media from in 
vitro organoids holds enormous promise in monitoring direct 
information regarding the status of the cells as well as the 
efficacy and toxicity of a drug on cells.[5] Accurate monitoring 
of biological functions of cells (e.g., levels of cell-secreted bio-
markers, enzyme, etc.)[6] requires detection and analysis of trace 
amounts of biomarkers of interest over an extended period 
of time.[7] For example, many drugs or toxic compounds may 
result in chronic cellular reactions or delayed cell responses 
and lead to gradually changing secretion of biomarkers typically 
at low abundance. Therefore, the development of an efficient 
biosensing platform capable of accurate, continual, and long-
term monitoring of biomarkers is needed to assess the biolog-
ical response of the cell or tissue construct to pharmaceutical 
compounds or toxic chemicals.[4c,8]
To address this challenge, several requirements shall be sat-
isfied when designing robust biosensors for biomarker moni-
toring. First, they should be able to detect trace amounts of bio-
markers (<1 ng mL−1) within complex biological environments 
such as cell culture medium, which usually contains a plethora 
of nonspecific proteins and interfering compounds. Second, 
the robust biosensor systems should be able to have continual 
monitoring capability every few hours or days for kinetics 
analysis of biomarkers over extended periods. Most of the 
current biosensing systems based on enzyme-linked immu-
nosorbent assay (ELISA),[9] surface plasmon resonance,[10] 
mass spectrometry (MS),[11] surface enhanced Raman spec-
troscopy,[12] as well as electrochemical (EC) and fluorescence-
based detection[13] inherently suffer from surface saturation 
upon binding of target molecules, limiting their multiple use 
in accurate and continual analysis of biomarkers.[14] To regen-
erate the probe, the entire interface must be reconstructed, 
which often requires harsh, time-consuming stripping proto-
cols.[15] Moreover, potential damage incurred to the sensor sur-
face during regeneration can also affect sensitivity.[16] Recently, 
various cleaning processes have been developed to regenerate 
sensor surfaces while maintaining their sensitivity.[5a,16b,17] 
However, these regenerated biosensors have not been shown 
for their ability to continually monitor secreted biomarkers by 
the organoids. Ideally, the robust biosensor systems should 
allow for harsh and/or complicated cleaning processes to 
enable repeated measurements lasting from hours to days in 
a continual manner without the need for replacement of the 
biosensors. This regeneration process is critical for reusing 
This is an open access article under the terms of the Creative Commons 
Attribution License, which permits use, distribution and reproduction in 
any medium, provided the original work is properly cited.
the sensors and must be properly designed. Successful regen-
eration of the sensor surface should clearly restore the orig-
inal sensor surface obtained after fabrication. In addition, the 
signal variation should be less than 5% of the initial measure-
ments while the sensitivity of the sensor should not be signifi-
cantly attenuated.[18] Third, the sensors should be scalable to 
allow for simultaneous or sequential monitoring of several bio-
markers. Fourth, they should be compatible with the microflu-
idics technology and enable convenient integration with biore-
actor platforms to achieve continual and long-term monitoring 
of dynamic cell or tissue behaviors.[19] Finally, the sampling 
should consume minimum volume due to the typically small 
amount (<few mL) of the medium circulating in most micro-
fluidic organoid platforms.
Among the many different biosensor systems currently 
existing, EC sensors possess unique advantages due to their 
excellent limit of detection (down to attomolar levels),[20] 
capacity of label-free detection, a wide linear response range, 
portability, suitability for long-term monitoring, and simplicity 
of fabrication compared to other techniques such as MS.[21] EC 
sensors can be conveniently functionalized with antibodies to 
achieve specific binding and detection of desired biomarkers, 
which potentially allows for robust surface cleaning when nec-
essary. In addition, EC sensors are amenable to microfabrica-
tion; hence, miniaturization of EC sensors using microfabri-
cated electrodes facilitates their integration into microfluidic 
platforms, allowing for suitable integration with organ-on-a-
chip systems. Using on-chip valves one can further conduct 
sophisticated fluid manipulation to achieve repeated measure-
ments and surface cleaning cycles in an automated manner 
through programmed computer controls. This feature permits 
labor-free testing reducing human errors, requires low sample 
volumes, and allows long-term testing. Furthermore, multior-
ganoid monitoring can be carried out using multiplexed sen-
sors for high-throughput applications, which has remained 
as a setback for other conventional testing techniques such as 
ELISA. In summary, microfluidic EC immunosensors equipped 
with built-in surface regeneration capacity can enable continual 
measurements of secreted biomarkers from organoid platforms 
and allow for reliable long-term evaluations upon drug and 
chemical exposures. In addition, they could have a great impact 
to the field since monitoring the metabolic state of cells can be 
a highly dynamic process. ELISA is usually done at end points 
and single times, which is a disadvantage since the continual 
changes in cellular response during testing are not captured. 
Therefore, the comprehensive state of the organoids can only 
be recognized by continual monitoring of the substrates and 
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their metabolites but not by taking a snapshot at a single point 
of time.[5c,d,22]
In this work, we report a unique label-free EC microfluidic 
immunobiosensor platform with a built-in regeneration capa-
bility for continual monitoring of cell-secreted biomarkers 
from human cell-based liver-on-a-chip. The fabrication of 
microfluidic valves on the same chip allowed one to carry out 
the regeneration and detection processes without any manual 
operations, which has been rarely achieved to date. The sensor 
utilizing EC impedance spectroscopy (EIS) measurements was 
adopted for label-free detection of liver biomarkers including 
human albumin and glutathione-S-transferase-alpha (GST-α) to 
monitor hepatotoxicity. Albumin is a representative biomarker 
of the healthy liver tissue synthesized by the liver and GST-α is 
another liver biomarker shown to increase following acute liver 
injury.[23] An electrode surface cleaning process was developed 
and systematically optimized for gold (Au) microelectrodes 
to enable successful regeneration of electrode surfaces upon 
sensor saturation. The microfluidic EC biosensors were subse-
quently integrated with a primary human liver-on-a-chip system 
where albumin and GST-α secreted by the liver organoids were 
continually monitored for up to 7 d. Changes in metabolism of 
the liver organoids were induced by the administration of dif-
ferent doses of a liver-toxic drug acetaminophen (APAP). The 
changes in the biomarker levels detected by the EC biosensors 
were compared with cellular viability and ELISA analyses to val-
idate the accuracy of our sensing platform. We believe that this 
robust microfluidic EC immunobiosensor system is capable 
of automated and continual detection of soluble biomarkers 
through repeated regeneration cycles within the physiological 
range down to nanomolar,[23] has not been reported to date. Our 
platform with carefully optimized functionalization, detection, 
and regeneration protocols will likely find widespread applica-
tions in cases where high-sensitivity, streamlined detection of 
biochemical species is required, such as clinical diagnostics, 
point-of-care diagnosis, single cell monitoring, in addition to 
screening of drug toxicity, efficacy, and pharmacokinetics in 
organ-on-a-chip systems.
2. Result and Discussion
2.1. Design and Optimization of a Label-Free EC 
Sensing Method
Microscale electrodes were designed to create an EC detection 
system with easy integration into microfluidic devices. The EC 
sensor system consisted of three electrodes, namely, a refer-
ence electrode (RE), a working electrode (WE), and a counter 
electrode (CE) as shown in Figure 1a. It should be noted that, 
with the built-in RE, we can maintain a desired and stable elec-
trical potential between the WE and electrolyte- or cleaning-
solution during the impedance measurement or cleaning 
process, respectively. The CE and WE were made of Au whereas 
the RE was made of silver (Ag). Au was selected as the mate-
rial for WE due to its relatively good stability, favorable electron 
transfer kinetics with high in-plane conductivity, biocompat-
ibility, and its ability to readily create covalent bonding for gen-
erating stable immobilization of receptors onto its surface. 
The microelectrodes were fabricated using a shadow mask 
and e-beam evaporation process. The lift-off and wet-etching 
methods were not suitable for the patterning of Ag electrodes 
mainly due to the weak adhesion between the titanium (Ti) 
adhesion layer and the Ag layer which resulted in the detach-
ment of the Ag layer during the washing steps. The washing 
steps are commonly used after removing the sacrificial photore-
sist layer using acetone or following the wet etching of the Ag 
layer using H2O2-based etchant solution. Shadow mask pro-
cessing can be easily utilized in microfabrication of Ag films 
since after peeling off the shadow mask from the wafer, the 
required patterns were realized on the glass substrate without 
the need for any wet processing. Furthermore, a palladium (Pd) 
barrier layer was deposited between the Au and the Ti layer and 
the Ag and the Ti layer, to improve the adhesion between the Ag 
and the Ti layer[24] and prevent the interlayer diffusion between 
Ti/Au/Ag layers during the annealing process (300 °C for 6 h in 
a furnace).[25] The annealing process allowed us to create robust 
microelectrodes resulting in minimal damage to the electrodes 
under harsh environments such as low and high pH solutions, 
corrosive solvents, and application of high electrical potentials. 
The microelectrode structures consisted of three layers, Ti/Pd/
Au or Ti/Pd/Ag with the thicknesses of 20 nm/20 nm/500 nm 
as depicted in Figure S1a (Supporting Information), whereas 
the geometry and the dimensions of the microelectrodes are 
shown in Figure S1b (Supporting Information). Following fab-
rication, the surface of the WE was observed to be uniform and 
smooth (root-mean-square (RMS) roughness: 3.02 ± 0.45 nm) 
as seen in the atomic force microscopy (AFM) image (Figure 1b 
and Figure S1c, Supporting Information). This is crucial for 
improving the uniformity in immobilization of antibodies on 
the electrode surface, which might help improve the antigen 
binding capacity and result in enhanced detection sensitivity of 
the sensor.[26] Furthermore, Figure S1d (Supporting Informa-
tion) shows the outcome of EIS measurements obtained from 
a bare microelectrode which followed the expected theoretical 
outcome, including a semicircle plot at high frequencies and a 
straight line at low frequencies characteristic of the diffusion-
limited charge transfer.
As shown in Figure 1c, the surface of the microelectrodes 
was functionalized with antibodies specifically chosen for cap-
ture of target antigens. To create the antigen-capture surface, 
the surface of the microelectrodes was first coated with a self-
assembled monolayer (SAM) by using 11-mercaptoundecanoic 
acid (11-MUA). Streptavidin (SPV) was next immobilized by 
covalent bonding on the SAM functionalized electrode in order to 
improve the alignment of antibodies. Then by using N-ethyl-N′-
(3-dimethylaminopropyl) carbodiimide (EDC)/N-hydroxysuccin-
imide (NHS) conjugation, a covalent bond was formed between 
the surface and the self-assembled monolayer where the carboxyl-
terminated alkyl surface was converted to an active NHS ester by 
reacting with 11-MUA. The EDC/NHS-coated surface was able 
to react with amine-containing SPV and create uniform patterns 
on the SAM. To recognize the specific target antigens, the bioti-
nylated antibodies (biot-Abs) were then decorated onto the SPV 
functionalized electrode surface via strong interaction between 
streptavidin and biotin.[27] This strong interaction was able to 
keep the receptors on the surface of microelectrodes during fluid 
flow from the bioreactor. The label-free detection mechanism of 
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the microfluidic EC sensor is based on the change of interfacial 
electron-transfer kinetics of the redox probe [Fe(CN)6]4−/3− sur-
rounding the electrode surface upon antibody–antigen binding 
(Figure 1d).[28] In a certain concentration range the amount of 
antigens captured on the functionalized electrode surface using 
antibodies is proportional to the antigens in the solution where 
the amount of antigens collected on the electrode surface were 
monitored by measuring the impedance of the electrodes.[29] 
Nyquist plots were obtained in the frequency range varying from 
10−1 to 105 Hz under a potential value of 0.10 V and modulation 
amplitude of 5 mV in 50 × 10−3 m K3Fe(CN)6. With the attach-
ment of more antigens, the measured the electron-transfer resist-
ance (Rct) value of the electrode was found to increase due to 
shielding of the redox probe [Fe(CN)6]4−/3− by antigens. Hence, 
the [Fe(CN)6]4−/3− solution was added to the sampling medium 
so that we could distinguish the deposition of each coating step.
After the binding of each biomolecule layer on the electrode 
surface, Rct of the electrodes was measured. In Figure 1e, a sig-
nificant semicircle curve appeared in the high-frequency region 
after immobilization of the SAM layers on the bare electrode. 
However, the signals at low frequencies representing the War-
burg impedance disappeared compared to that of bare electrode 
(Figure S1d, Supporting Information). The diameter of the 
semicircle of the Nyquist plot (characterized by Rct) was found 
to increase from about 3 to 50 kΩ after the formation of SAM 
and increased further upon the deposition of SPV, biotinylated 
anti-albumin, and media blocking layers due to the decreases 
in charge transfer efficiency of [Fe(CN)6]3−/4− as a result of accu-
mulated insulating layer on the electrode surface. Figure S1e 
(Supporting Information) shows an equivalent circuit model for 
obtained Nyquist curves after immobilization of the antibody 
layer. Here, Rs, Rct, and Cdl represent Ohmic resistance of the 
www.advancedscience.com
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Figure 1. Detection principle of the label-free EC biosensing system by using microelectrode. a) A photograph of the fabricated microelectrode having 
RE (Ag), WE (Au), and CE (Au). b) AFM image of the bare WE surface. c) A schematic illustration for immobilization of antibody using SPV on the 
surface of the microelectrodes. d) Schematic of charge transfer after antigen binding upon antibody–antigen binding for [K3Fe(CN)6]3−/4− redox process. 
e) Nyquist plots obtained from measurements before and after the deposition of each layer (SAM, SPV, biotinylated anti-albumin, media blocking). 
f) Selectivity study of albumin biosensor showing the effect of media incubation (left side from dotted line). GST-α, albumin, and CK-MB incubations on 
the GST-α biosensor represented showing the obtained normalized Rct values (right side from dotted line). g) Nyquist plots drawn for different standard 
human albumin concentrations. h) Calibration curve for human albumin plotted according to the normalized Rct (Rct antigen/Rct media) values.
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electrolyte solution, the charge transfer resistance of the redox 
([Fe(CN)6]3−/4−), and the double layer capacitance, respectively.
To improve the sensitivity of the EC biosensors, several 
parameters affecting the deposition process were optimized. 
The change in normalized Rct values with respect to incuba-
tion time is shown in Figure S2 (Supporting Information) for 
different functionalization steps. After 1 h of incubation, the 
normalized Rct values of different functionalization steps did 
not show a significant change (Figure S2, Supporting Informa-
tion). Therefore, the incubation times for SAM (Figure S2a, 
Supporting Information), SPV (Figure S2b, Supporting Infor-
mation), biotinylated anti-albumin coatings (Figure S2c, 
Supporting Information), and the media blocking steps 
(Figure S2d, Supporting Information) were determined to be 
1 h. Subsequently, the sensing performance of optimized EC 
biosensors was evaluated inside a complex sample solution. 
However, the use of complex media having high concentra-
tions of nonspecific binding proteins that are 105 times higher 
than those of the analytes of interest in the media, may alter 
the measurements and lead to incorrect results.[30] To assess 
the applicability of our biosensor toward real samples, we car-
ried out measurements using cell culture media, which usu-
ally included high concentrations of fetal bovine serum (FBS) 
containing around ≈99 mg mL−1 bovine serum albumin and 
other molecules but not the target antibody, that is, human 
serum albumin. This target-free cell culture media was incu-
bated with the electrodes twice after immobilization of the 
biotinylated albumin antibodies. The Rct value obtained from 
electrodes following second media incubation displayed results 
that were similar to the ones obtained from the electrodes after 
the first media incubation step (Figure 1f and Figure S3a, Sup-
porting Information, left side of the dotted line). These results 
indicated that the incoming human albumin antigens specifi-
cally bond to the human albumin antibodies even when the 
media included a large amount of nonspecific binding pro-
teins such as bovine serum albumin. We then obtained the 
calibration curve in the detection range of 0.01–100 ng mL−1 
with human albumin spiked to cell culture media as shown 
in Figure 1g,h. As the albumin concentration was increased 
from 0.01 to 100 ng mL−1 in cell culture media, the impedances 
between the WE and CE electrodes were found to increase as 
expected and an increase in Rct values was thus observed. In 
addition, the EC sensor was capable of detecting albumin with 
a limit of detection (LOD) of 0.023 ng mL−1 and a sensitivity 
of 0.95 (log(ng mL−1))−1. Importantly, the measured LOD value 
was found to be lower than that reported in the previous study 
which used an impedance-based biosensor (1.6 ng mL−1).[31] 
Due to the fact that the SPV might induce the orientation of 
antibody on the surface of the electrode during the immobiliza-
tion process, improved antigen binding capacity is anticipated 
comparing with randomly immobilized antibody by using 
glutaraldehyde as a conventional cross-linker.[26] Furthermore, 
our impedance-based sensor showed lower LOD than amper-
ometric biosensor (1 µg mL−1).[32] Compared to amperometry 
requiring a wide potential range to obtain a current signal, 
the impedance measurement is performed in a range of fre-
quencies, using alternating current of a very narrow range of 
small potentials (less than 10 mV). Therefore, the impedance is 
less destructive than amperometry to the measured biological 
interactions. This small perturbation of the electrochemical 
system can be perceived as stationary, where measurements 
with high precision are possible.[33] Consequently, our sensor 
was more sensitive than those previously reported for detecting 
trace amounts of albumin.
To demonstrate the selectivity of our sensor, we introduced 
different concentrations of other biomarkers to the surface 
designed to capture GST-α , which is a biomarker for dam-
aged liver tissue. In this experiment, 1 ng mL−1 albumin and 
1 ng mL−1 creatine kinase-MB (CK-MB) biomarkers, which can 
be secreted from damaged cardiac tissue, were used as the non-
specific antigens. As shown in Figure 1f (right side of the dotted 
line), the Rct signal obtained from media with 1 ng mL−1 GST-α 
was twice as high as the Rct signals obtained from media alone. 
However, there were no significant differences in the Rct values 
of GST-α sensors obtained from media spiked with CK-MB and 
albumin. This result should be attributed to the fact that our 
immunosensor only responded to the GST-α antigen within 
the cell culture media. These measurements indicated that the 
developed EC sensor possessed high sensitivity and the selec-
tivity and can be used for analyzing biomarkers from target 
tissue, and the system can be customized for the detection of 
other biomarkers, from various cell culture media containing 
large amounts of proteins with minimum sample depletion. 
Despite its advantages, one challenge with the EC sensor is 
that the electrodes tend to saturate rapidly making this a single-
use sensor. Hence, if one were to take multiple measurements 
or to monitor the organoids for longer durations, the sensors 
needed to be changed with new ones after each measurement. 
The saturation of the electrode surface is concentration- and 
time-dependent. During our experiments, we observed that the 
EC sensor became saturated after conducting several measure-
ments (up to ten times at 10 ng mL−1 albumin as antigen with 
incubation time of 1 h) (Figure S3b, Supporting Information), 
showing that the EC sensor surface covered with biotinylated 
antibody can capture a maximum of ≈100 ng mL−1 human 
albumin before saturation. Therefore, to carry out continual 
measurements of secreted biomarkers from organoid samples 
over longer periods a regeneration process is needed to clean 
the surface of the electrodes.
2.2. Off-Chip Optimization of the Regeneration Process
The EC sensor was shown to have strong binding affinities 
including the covalently bonded SAM, SPV-biotin, and anti-
body–antigen. Therefore, the EC desorption method was 
selected to remove all the molecules residing on the surface of 
the saturated electrodes by etching thin layers of Au and carry 
out an electrolysis process at >±1 V (Figure 2a). To create a reli-
able regeneration process for the EC sensor, we optimized the 
cleaning protocol with the goal of recovering the initial current 
or impedance value after removal of all immobilized layers 
attached to the surface. The initial values were obtained from 
as-fabricated bare electrodes (Figure S4a, Supporting Informa-
tion). A two-step cleaning process was developed and optimized 
for the Au microelectrodes by treating their surface with H2SO4 
and followed by K3Fe(CN)6 exposure under the application of 
electrical sweep. Sulfuric- and cyanide-based cleaning solutions 
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containing H2SO4 and K3Fe(CN)6 have been used to clean metal 
surfaces.[34] The first cleaning step was optimized as follows: 
use of 10 × 10−3 m H2SO4, applied potential from 0 to 1.8 V at a 
100 mV s−1 scan rate, and conducting an electrical sweep for five 
times where the process was found to be sufficient to remove 
the majority of antibody/antigens by breaking the thiolAu 
bonds. It was demonstrated that the electrical current meas-
ured at a potential of 125 mV was found to recover ≈80% of the 
www.advancedscience.com
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Figure 2. Off-chip optimization of microelectrode regeneration. a) Schematic illustration of the microelectrode regeneration method with cleaning 
solution and application of electrical sweep potential. b) Nyquist plots drawn before and after regeneration of the microelectrode. c) Change in Rct value 
before and after regeneration process represented by histograms with error bars (n = 3). AFM images of the microelectrode surface of d) after antigen 
immobilization and e) after regeneration. f) SEM image of regenerated microelectrode surface. EDX analysis of the spot shown by red arrow in SEM 
image. g) Schematic illustration of the microelectrode having different Au layer thickness, 150 and 500 nm. h)The peak current (IpA (A)) at 0.16 V after 
repeated regeneration of the microelectrodes with two different Au layer thickness (150 and 500 nm) (n = 3). i) AFM image of 25 times regenerated 
microelectrode surface. j) Histograms with error bars showing the change of RMS roughness (n = 3) and k) thickness of bare, 1 time, and 25 times 
regenerated microelectrode surfaces (n = 3).
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original current obtained after antigen binding (Figure S4, Sup-
porting Information). However, when we further increased the 
number of electrical sweeps to recover ≈100% of the electrical 
current, the RE electrode usually underwent damage. To solve 
this problem, we used an additional cyanide-based cleaning 
step to remove the rest of molecules by etching them from the 
Au layer via the formation of AuCN− or Au(CN)−2 on the surface 
of the Au electrode in a K3Fe(CN)6 solution under an electrical 
sweep.[35] Therefore, after applying the second cleaning step 
(50 × 10−3 m K3Fe(CN)6, applied potential: −1.2 to 1.2 V, scan 
rate: 100 mV s−1, number of electrical sweeps: 3), the electrical 
current measured from the cleaned electrodes was found to be 
very similar to that measured from the as-fabricated electrodes 
and was significantly higher than that measured from the 
electrodes after antigen detection, as expected. After optimiza-
tion, combination of five cycles of H2SO4 and three cycles of 
K3Fe(CN)6 cleaning was found to retrieve ≈100% of the signal 
obtained from as-fabricated electrodes. In addition, the Nyquist 
plot obtained from the electrodes cleaned using the optimized 
cleaning process was similar to the one obtained from as-fab-
ricated Au electrodes (Figure 2b). No significant differences in 
Rct values were observed from as-fabricated and cleaned elec-
trodes (Figure 2c). To validate our cleaning process, we utilized 
a different cleaning protocol which relied on the EC desorption 
of SAM in PBS using a cathodic voltage pulse.[36] Figure S4b 
(Supporting Information) shows the cyclic voltammetry (CV) 
scans after cleaning of the electrodes in PBS using a DC pulse 
at −1.8 V for 30 s. This cleaning method employing PBS as 
cleaning solution, however, did not achieve the same value of 
the electrical current measured from the cleaned electrode as 
compared to the one obtained from as-fabricated electrodes.
To investigate the morphological effects of each of the 
cleaning procedures onto the electrodes, AFM analysis was 
used to examine the roughness and the thickness of the cleaned 
microelectrodes under various conditions. The as-fabricated Au 
microelectrodes displayed a homogeneous and smooth surface 
(RMS roughness: 3.02 ± 0.45 nm) (Figure 1b). As expected, the 
microelectrodes with captured antigens showed the increased 
surface roughness (RMS roughness: 18.49 ± 6.89 nm) since 
SAM/SPV/biot-Ab/antigen layers had accumulated on the elec-
trode surface (Figure 2d). After treating the electrodes with a 
solution consisting of H2SO4 and K3Fe(CN)6 under a voltage 
sweep, the antigens bound to the electrodes were found to 
be removed, resulting in a decrease in the electrode surface 
RMS roughness with values up to 10.46 ± 0.99 nm (Figure 2e). 
However, after each cleaning step, it was found that the sur-
face roughness of the Au microelectrodes increased due to the 
etching of thin Au layers by the cleaning solution. This conclu-
sion was also supported by Figure S5 (Supporting Information), 
which shows the results from samples that were characterized 
for RMS roughness and average thickness.
To determine whether the increased surface roughness after 
the cleaning process was caused by either re-adsorption of the 
biomolecules detaching from the surface or the damage of the 
electrode during the etching step, SEM and the energy-disper-
sive X-ray (EDX) spectroscopy measurements were carried out. 
As shown in Figure 2f, the cleaned Au microelectrode con-
tained dark spots (red arrow) on the surface which resulted in 
increased surface roughness. According to the EDX spectra, the 
composition of the spots on the regenerated electrode surface 
(red arrow in Figure 2f) was mainly Au, which was similar to the 
EDX spectra obtained from as-fabricated electrodes (Figure S6, 
Supporting Information). Accordingly, the developed cleaning 
method successfully removed SAM/SPV/biot-Ab/antigen mol-
ecules attached on the electrodes without re-adsorption of the 
detached molecules. However, the cleaning process was found 
to decrease the thickness of the electrodes and hence could 
only be used for a finite number of times due to the etching of 
the Au layer during multiple cleaning steps. Accordingly, the 
thickness of Au layer was found to play a key role in increasing 
the number of electrode regeneration cycles and ensuring the 
high sensitivity of the sensor for long-term and continual moni-
toring. To evaluate the effect of Au thickness in increasing the 
number of electrode regeneration steps, the microelectrodes 
with two different thicknesses (namely, 150 and 500 nm) were 
fabricated (Figure 2g). We then tested the regeneration ability 
of an electrode until it became unusable. We functionalized the 
surface of the electrodes by immobilizing SAM/SPV/biot-Ab on 
the surface of the working electrodes through covalent bonding 
between the electrode and the SAM. The antibody immobilized 
microelectrode was next regenerated. We then obtained CV 
scans from regenerated electrodes in a 50 × 10−3 m K3Fe(CN)6 
solution. When using a 500 nm thick microelectrode, we were 
able to obtain the same or similar EC oxidation signals from 
the redox probe (IpA) for up to 25 regeneration cycles as shown 
in Figure 2h. In comparison, the 150 nm thick microelectrode 
showed a significantly decreased IpA after about nine regenera-
tion cycles. Therefore, by moving to thicker Au layers (from 150 
to 500 nm) in the microelectrode fabrication process, we were 
able to significantly increase the regeneration capability of the 
sensors. The thickness of electrode is the effect of the required 
number of regeneration steps. The electrode that was regener-
ated for 25 times exhibited a significant increase in the rough-
ness and maintained half of its thickness compared to the as-
fabricated electrodes and the electrodes that were regenerated 
only once (Figure 2j,k). Besides, the EDX results displayed that 
the electrodes regenerated for 25 times seemed to have similar 
elemental composition of Au compared to as-fabricated elec-
trodes and the electrodes that were regenerated once (Figure S6, 
Supporting Information).
2.3. Design, Fabrication, and Control of the Automated 
Microfluidic EC Biosensor
We next developed a sensor platform with automated regenera-
tion capability for multiple biosensor measurements. To do this, 
a programmable microfluidic system is required for automated 
sample handling, including (1) delivery of solutions at defined 
times to regenerate the sensor surface and will allow the sensor 
for long-term (weeks) continual assays, and (2) delivery of sam-
ples from bioreactors to the sensor chip for in-line bioassays. 
To achieve these requirements, the EC biosensor was integrated 
into a microfluidic chip, which had 13 inlet microchannels (red 
lines) with hemicylindrical shapes and their associated micro-
valves (green line) for manipulating the injection of required 
reagents and samples (Figure 3a–c and Figure S7a, Supporting 
Information). The rounded design improved the closing of the 
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microfluidic channels by blocking them with the programmed 
N2 gas-actuated microvalves, specifically for ethanol-based rea-
gents such as SAM (Figure 3d).[37] The microvalves and the 
reagent reservoirs were controlled by WAGO controllers with 
a custom-written MATLAB code (Figure S9, Supporting Infor-
mation, and Figure 3e), indicated by the time-lapse images of 
the liquid flow through microfluidic channels and the detec-
tion chamber upon opening and closing of the valves. After 
the liquid sample reached the electrode area, it was gradu-
ally replaced by another liquid solution where the whole pro-
cess took ≈5 s (Figure 3f). The flow rate in each channel was 
found to increase as the pressure in the channel was elevated 
(Figure 3g). The main channel (PBS) had the highest flow rate 
during the experiments due to its large and straight channel 
design without any curvature and/or turns. In other channels, 
the fluid flow rates were found to vary depending on the spe-
cific pathways. It was concluded that by changing the operating 
pressure, the flow rates in different channels could be tuned 
within a reasonable range. In addition, the bubble trap design 
in the chamber included pillars with 500 µm diameters which 
was also added to the main channel of the electrode area to pre-
vent disruptions from the bubbles during the cleaning process, 
EC detection, and the flow of drugs. The diameters of the bub-
bles were found to dramatically decrease and they were found 
to disappear after about 35 s when using a chip with pillars 
having diameters of 500 µm (Figure S8, Supporting Informa-
tion). In this microfluidic setup, the introduction of all the 
reagent solutions into the chip can be completely achieved in 
an automated manner, therefore eliminating the possibility of 
releasing toxic reagents including K3Fe(CN)6, SAM, and ethanol 
from the electrochemical sensing unit to the media in the bio-
reactor.[38] Furthermore, during the impedance measurements 
using 50 × 10−3 m K3Fe(CN)6 solution, we block the flow to the 
detection chamber upon closure of the valves to obtain accurate 
impedance measurements and to reduce noise. It should be 
noted that, during the PBS washing step no electrical potential 
was applied to avoid any potential corrosion of the electrode.
2.4. Characterization of an Automated Microfluidic EC Chip 
with Regeneration Ability
Using an on-chip system, the calibration curve for albumin 
was obtained as shown in Figure 4a. The fabricated EC sensor 
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Figure 3. Design, fabrication, and control of the automated microfluidic EC biosensor. a) Photograph of the EC microfluidic chip bonded with micro-
electrode. b) Labeling of the microfluidic channels and the valves with corresponding flowing solutions for fully automated biosensing measurements. 
c) Three-layered microfluidic chip consisted of microfluidic channel, thin membrane, and valve channel layer. d) Schematically represented working 
principle to open and close the microfluidic channel by the push-down thin membrane according to gas pressure. e) Time-lapsed picture of microfludic 
EC chip showing the color changes in the main channel for PBS and detection chamber upon opening and closing of the valves. f) Time required for 
changing the chemicals at the electrode area demonstrated by using food dyes. g) Measured flow rates at different channels under various gas pres-
sures (n = 3).
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was capable of detecting albumin with a LOD of 0.09 ng mL−1 
and a sensitivity of 1.35 (log(ng mL−1))−1. It appeared that the 
linear portion of the semilog calibration curve had a higher 
slope compared to the one obtained using the off-chip method, 
demonstrating a higher sensitivity for the on-chip immu-
noassay presumably due to the automated handling and 
manipulation of liquids in the microfluidic chip. In addition, 
the on-chip measurement had a LOD of 0.09 ng mL−1, which 
was better than the one obtained from ELISA measurements 
(0.2 ng mL−1) (Table S1, Supporting Information). Overall, our 
microfluidic EC sensor showed better sensitivity, lower LOD, 
wider detection range, and required smaller sample volume 
compared to the conventional ELISA assay specific for albumin 
detection. We then optimized the parameters for cleaning of 
the microelectrodes using cleaning solutions with and without 
flow in a microfluidic chamber (Figure 4d). Initially, the micro-
electrode was regenerated under optimized regeneration con-
ditions using an off-chip system (Figure 2b), which applied an 
electrical sweep potential for five times in 10 × 10−3 m H2SO4 
(applied potential: 0–1.8 V; scan rate: 100 mV s−1) and 50 × 
10−3 m K3Fe(CN)6 (applied potential: −1.2 to 1.2 V; scan rate: 
100 mV s−1), respectively. However, we found that the current 
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Figure 4. On-chip optimization of regeneration method and sensing performance of repeated regeneration under automated manner. a) Nyquist plots 
for different standard human albumin concentrations. b) Calibration curve for human albumin plotted according to the normalized Rct (Rct antigen/Rct 
media) values (n = 3). c) The resulting regeneration efficiencies as recovered current rate which was obtained from the normalized peak current (IpA 
(A)) at 0.16 V with and without flow conditions in microfluidic chip. d) Schematics of regeneration process with and without flow conditions in micro-
fluidic chip. e) The peak current measured at a potential of 0.16 V after repeated regeneration of the microelectrodes. Histograms showing f) the RMS 
roughness data (n = 3) and g) thickness recorded based on AFM measurements for off-chip and on-chip cleaning conditions (n = 3). h) AFM image 
of the microelectrode surface after on-chip cleaning. i) Change in normalized Rct value of antigen detection according to several number of automated 
regeneration (n = 3).
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obtained from the regenerated electrodes was only about 53% 
of the current obtained from the as fabricated electrodes (no. 
1 in the table in Figure S10, Supporting Information). This 
result was due to the re-adsorption of the detached molecules 
to the electrode surface since there was no flow of the cleaning 
solution in the microfluidic chamber. However, the introduc-
tion of the cleaning solution under a dynamic condition (flow 
rate: 1000 µL h−1) during the removal of the detached molecules 
under an electrical sweep significantly improved the regen-
eration process. It was found that the CV curve and IpA value 
obtained from the cleaned electrode under 1000 µL h−1 flow rate 
was more similar to the one obtained from the as-fabricated 
Au electrode compared to that obtained from the cleaned elec-
trode without flow under the other conditions (Figure 4c and 
Figure S10, Supporting Information). Flows of cleaning solu-
tions onto the electrodes were found to efficiently remove 
detached molecules from the surface of electrodes and prevent 
their re-adsorption to the electrode surfaces (Figure 4d). After 
optimization of the cleaning process using an on-chip system, 
we determined that the microelectrodes could be successfully 
regenerated for at least 18 times as confirmed by the generation 
of the CV curves that were similar to the ones obtained from the 
as-fabricated electrode (Figure S11, Supporting Information). 
Furthermore, the current peaks (4.8 × 10−5 A) obtained from 
an electrode regenerated 18 times were similar to that obtained 
from the as-fabricated electrode (4.3 × 10−5 A) (Figure 4e) with 
a maximum fluctuation of 0.9 × 10−5 A. To confirm the effect of 
flow of the cleaning solutions to the roughness of cleaned elec-
trode, an AFM measurement was used to analyze the roughness 
of a microelectrode surface regenerated 18 times using cleaning 
solutions with and without flow. As shown in Figure 4f,g, the 
RMS roughness values were similar to those obtained from a 
bare electrode than those obtained from surface undergone an 
off-chip regeneration process even though the thickness of the 
microelectrode which was regenerated under flow was smaller 
than that of the one regenerated without flow. Furthermore, 
AFM image (Figure 4h) displayed a smoother electrode surface 
after the on-chip regeneration process compared with that of off-
chip regeneration process (Figure 2e). Consequently, we found 
that by supplying the cleaning solutions onto the electrodes 
under a continuous dynamic flow can help to efficiently remove 
the detached molecules from the surface of electrodes and pre-
vent their damage during the cleaning process.
To confirm the ability to carry out continual EC detection 
steps using electrodes with an integrated regeneration system, 
the EC microfluidic chip with microelectrodes were directly 
connected to a WAGO controller-driven valve controlling unit 
and a potentiostat (Figure 3 and Figure S9, Supporting Infor-
mation) and the electrodes were regenerated up to 5 cycles 
(Figure 4i). After each regeneration process, 10 ng mL−1 of 
albumin concentration was measured. Relative Rct values were 
determined from the Nyquist plots obtained after each regen-
eration cycle where 5 regeneration cycles were successfully 
achieved and the results were found to be consistent for up to 
4 regeneration cycles. It was found that the sensitivity decrease 
after 4 times of regenerated microelectrode is likely due to 
the increased roughness of microelectrode surface, while the 
reason for the roughness change should be attributed to the 
etching of Au due to potential sweep and chemical treatment. 
However, in Figures 2f and 4e and Figure S11 (Supporting 
Information), the peak potential and current of the redox probe 
[Fe(CN)6]4−/3− surrounding the electrode surface did not signifi-
cantly change upon multiple regeneration processes, indicating 
that the microelectrode set after these many regeneration cycles 
had the possibility to detect an antigen. To this end, it could 
become a problem if we want to measure a very low amount 
of antigen concentration. However, it is still possible for the 
regenerated sensor, even after 4 cycles, to detect the increase 
and decrease in the level of antigen using predetermined cali-
bration curves, although at the expense of decreased sensitivity. 
Based on the working mode of the microfluidic chip for each 
cycle, the electrodes were exposed to chemical flows ≈4 h. This 
length of time most probably caused more etching of thin 
layers of Au than expected. In addition, the current EC micro-
fluidic chip design such as the bonding process and the dura-
bility of the membrane, and other unoptimized factors could be 
other limitations preventing the achievement of higher number 
of regeneration steps.
2.5. Continual Monitoring of Cell-Secreted Biomarkers 
from Bioreactor Samples
We next analyzed the performance of our microfluidic EC bio-
sensor to monitor biomarkers secreted by human liver orga-
noids hosted inside microfluidic liver bioreactor. In our previous 
study, microfluidic-based bioreactors were developed using 
advanced platforms that recapitulated the biology and physi-
ology of human organs on an integrated microfluidic circuitry 
for drug and toxin screening.[39] To fabricate the human liver 
bioreactor, human primary hepatocyte spheroids-laden gelatin 
methacryloyl (GelMA) prepolymer solutions were bioprinted 
into a microfluidic bioreactor with ≈9 × 105 cells in microdot-
array form (diameter: ≈600 µm) (Figure 5a and Figure S12, 
Supporting Information). To conduct hepatotoxicity assess-
ment studies, we used acetaminophen (APAP) as a model drug 
and evaluate the response of the platform against this drug. It 
is well known that exposure of hepatocytes to APAP can alter 
protein secretion rates which will be mediated by metabolic 
activities.[40] In this study, 5 × 10−3 and 10 × 10−3 m APAP con-
centrations were utilized to induce hepatotoxicity as per the 
optimized dose reported in our previous study and other pub-
lished literature.[39d,41] To monitor albumin and GST-α levels, 
sample solutions were collected from the bioreactor and then 
delivered into one of solution reservoirs that was connected 
with the sampling microchannel on the EC microfluidic chip by 
manual operation. For the EC microfluidic chip, automatically 
controlled valves and microfluidic channels were programmed 
to allow the solution entry at the predefined time points in con-
junction with the measurements obtained using the potentio-
stat. The secretion rate of albumin was found to increase from 
day 1 through day 7 for the bioreactor without APAP treatment, 
as expected (Figure 5b). However, when the cells were exposed 
to media containing 5 × 10−3 and 10 × 10−3 m APAP, the pro-
duction rates of albumin from day 1 through day 7 were found 
to statistically decrease to more than half of its initial value. To 
indicate the changes in the level of secreted GST-α, the EC cal-
ibration curve for GST-α is shown in Figure S13 (Supporting 
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Information) and the GST-α biosensor was found to detect up 
to 50 ng mL−1 with a LOD of 0.01 ng mL−1. Therefore, we found 
that the developed GST-α biosensor can detect GST-α secretion 
within the physiological range which is in nanomolar concen-
tration.[23] When the cells were treated with 5 × 10−3 m APAP, 
the production rates of GST-α obtained from day 1 through day 
7 were found to be the same with the values obtained from the 
control group (Figure 5c). However, for the organoids treated 
with 10 × 10−3 m APAP, the production of GST-α was found 
to significantly increase at day 1 and had finally increased by 
ten times at day 7 in comparison with the control sample. The 
albumin concentration was found to decrease whereas the GST-
α concentration was found to increase after the liver organoids 
were exposed to APAP.
To demonstrate the ability of the EC biosensor to monitor 
cell-secreted biomarkers from a microfluidic bioreactor, the 
data obtained from the EC biosensor were compared with the 
data obtained from ELISA measurements. This comparison 
revealed that the change in the levels of the two biomarkers 
obtained by the EC biosensor and the ELISA data agreed well 
Figure 5. On-chip detection of biomarkers secretion from primary hepatocyte bioreactor construct upon drug treatment. a) Sealed and primary 
hepatocyte spheroid patterned bioreactor with magnified view of incubation chamber and microscope image of a printed spheroid. b) Continual EC 
measurements of albumin (n = 3) and c) GST-α production rate in primary hepatocyte bioreactor with control, 5 × 10−3 and 10 × 10−3 m APAP exposure 
conditions (n = 3). d) Live/dead staining for control, 5 × 10−3 m APAP exposed and 10 × 10−3 m APAP exposed primary hepatocyte spheroids in biore-
actor at days 1, 3, 5, and 7. e) Schematic diagram of the microfluidic EC biosensing system integrated with organ-on-a-chip for continual monitoring 
of a target biomarker by automated manner. f) Automatic continual EC measurements of albumin and GST-α production rate in primary hepatocyte 
bioreactor without drug treatment.
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with each other (Figure S16, Supporting Information). To 
obtain a qualitative comparison between the measured values of 
cell-secreted biomarkers and the viability of spheroids, we fur-
ther performed a cell viability assay after the cells were exposed 
to different APAP concentrations. As shown in Figure 5d, 
the control (no APAP) showed a high viability until the end 
of day 7. When the cells inside the bioreactors were exposed 
to APAP, the viability of the cells was found to decrease with 
increasing APAP dose and the incubation time. For the biore-
actors treated with 5 × 10−3 m APAP, many live cells were still 
found inside the bioreactors at the end of 7 d, indicating par-
tial cytotoxicity of the drug at such an elevated concentration 
of APAP. However, 10 × 10−3 m APAP exposure significantly 
decreased the cell viability after day 7. These results correlated 
well with results obtained from the literature and our previ-
ously published study.[42] Remarkably, our data showed that the 
trend in cell viability at each day was consistent with the varia-
tion of albumin and GST-α production rates at the same time 
points. This observation was also in agreement with hepatotox-
icity studies reporting APAPs impact on cell viability and the 
biomarker secretion rates.[39d,43] Such accurate measurement 
proved the reliability of the on-chip immunoassay for detection 
of the target biomarkers using our EC biosensors.
To confirm the performance of the EC biosensors with an 
electrode regeneration capability in continually monitoring 
cell-secreted biomarkers in a microfluidic bioreactor, an auto-
mated integrated system was assembled to achieve long-term, 
on-line monitoring of the changes in the albumin and GST-α 
levels without APAP treatment (Figure 5e). The EC sensing 
platform was directly connected to the bioreactor hosting the 
human primary hepatocyte-laden liver organoids. After sensing 
of biomarkers from the bioreactor samples at day 0, the micro-
electrode surface was cleaned using the optimized cleaning pro-
tocol. All the necessary individual biomolecules including SAM, 
EDC/NHS, SPV, biot-Ab, and media were sequentially injected 
into the microchamber to refunctionalize the cleaned micro-
electrodes. Based on the obtained standard curve, the concentra-
tions of bioreactor samples at 1, 2, 3, 4, and 5 d were calculated 
(Figure 5f). The secretion rate of albumin was found to increase 
from day 1 through day 5 for the samples collected from the bio-
reactors. However, the production rates of GST-α obtained from 
day 1 through day 7 was found to be the similar with the values 
obtained from day 0. Therefore, our automated and integrated 
system was able to achieve long-term and on-line monitoring 
with multiple biomarkers using the reusable microelectrode. 
Furthermore, our unique sensor platform prevented variability 
due to human errors, unlike most of EC-based antigen sensors 
which are operated manually or semiautomatically.[44] However, 
these methods are relatively complicated due to sophisticated 
protocols, and are time-consuming due to the longer incubation 
times required for the measurements. In particular, the total time 
required for a complete detection and regeneration cycle is ≈4 h, 
including the functionalization of the microelectrode (174 min), 
the detection of antigen (58 min), and subsequent regeneration 
cycle (18 min). However, after functionalization each sensor can 
be used for multiple detections before reaching saturation (e.g., 
around ten times upon multiple detections of 10 ng mL−1 human 
albumin, Figure S3b, Supporting Information), allowing for more 
frequent measurements; moreover, multiple sensing units can be 
integrated to enable alternative usage when even shorter inter-
vals are necessary for antigen detection. Therefore, our automatic 
microfluidic system can efficiently improve the experiments in 
the following aspects: (1) fully automated operation of electrode 
functionalization, detection, and regeneration; (2) label-free 
antigen detection process that requires minimum medium deple-
tion; (3) regenerative capability of the electrode surface upon satu-
ration with captured antigens; and (4) cost-effectiveness due to the 
use of the miniaturized electrodes and microfluidic platform. All 
advantages of this automatic microfluidic EC biosensing module 
are superior to existing sensing systems in performing long-term 
and continual monitoring of biomarkers.
3. Conclusion
In this paper, we have developed a reusable label-free microflu-
idics EC biosensor and integrated this system with a human orga-
noids system. The objective was to design a system for on-line and 
long-term detection of cell-secreted biomarkers. The impedance-
based biosensor was capable of detecting albumin and GST-α 
with an LOD of 0.023 and 0.01 ng mL−1 from complex biological 
environments such as cell culture medium which usually contains 
a plethora of nonspecific proteins and interfering compounds but 
trace amounts of biomarkers of interest. In addition, we have suc-
cessfully optimized the electrode thicknesses and implemented 
the off-chip detection process into an on-chip microfluidic detec-
tion process with regeneration for continual monitoring of bio-
markers secreted from organoids which are exposed to different 
concentrations of drugs under perfusion flow. The optimized 
cleaning strategy developed for the regeneration process enabled 
long-term monitoring without any significant loss in sensor sen-
sitivity for up to 25 regenerations. This microfluidic-integrated 
label-free EC biosensor with an on-chip built-in regeneration capa-
bility was successfully controlled in a fully automated manner. 
Moreover, the real media samples from a human liver-on-a-chip 
bioreactor were measured using this platform, which showed 
similar results with those obtained from ELISA tests before and 
after APAP treatment. This work provided a novel and unique 
universal strategy for the construction of automated microfluidic 
based sensors for continual monitoring of the specific biomarkers 
involved in monitoring of cells for drug toxicity.
4. Experimental Section
All experimental methods are described in the Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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